MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

P = Substitute	for form 1449B	/PTO		Complete if Known	
	ION DISCLO		Application Number	10/029,401	RECEIVE
STÄTEMEI	NT BY APPL	ICANT	Filing Date	12/21/2001	TIE OLIVE
MAY 1 9 2003 21			First Named Inventor	ROGER A. SABBADINI	
<u> </u>			Group Art Unit	1654	MAY 2 2 2003
(use as many	sheets as ne	cessary)	Examiner Name	WARRY LEARY	
Sheets TRAVE 1	of	1	Attorney Docket Number	078853-0306	TO LO GRAPH A CONTRACTOR OF THE CONTRACTOR OF TH
					TEOH OENTER 1000 230

	U.S. PATENT DOCUMENTS										
Examiner Initials*	U.S. Patent Document Cite	Pages, Columns, Lines, Where Relevant Passages or Relevant CLASS Figures Appear,									
CL.	A1 5,989,803 Tabas et al. November 23, 1999	435/4									

				FO	REIGN PATENT DOCUMEN	ITS		
Examiner Initials*	Cite No.	Fo Office ³	reign Patent C Number ⁴	Occument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of I Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76
FC	A2.	WO	01 37836 A		Emory University	May 31, 2001		
CC	A3	WO	01 71045		Millennium Pharmaceuticals, Inc.	Sept. 27, 2001		1
CC	A4	, wo	00 56135		Regents of the University of California	Sept. 28, 2000		1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
CC	A5	Sabbadini et al., "The MIRF trial: Predicting the incidence and severity of CAD using serum sphingolipids." Circulation, 102: 11699, 2000 (Abstract).	
CC	. A6	Nakajima et al., "Expression and characterization of Edg-1 receptors in rat cardiomyocytes: Calcium deregulation in response to sphingosine 1-phosphate." European Journal of Biochemistry, 267: 5679-5686, 2000.	! !
CC	A7	Huwiler et al., "Physiology and pathophysiology of sphingolipid metabolism and signaling." Biochimica Et Biophysica Acta, 1485: 63-99, 2000.	<u> </u>
LC	i A8	International Search Report issued in PCT Application No. PCT/US01/50785	<u> </u>
	7 - ;		! !

The state of the s	
Examiner Signature Course Sugnature	Date 4/2004
*FYAAMAFD: 4-W-13-4	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Page 1 of 21 Form PTO-1449 SERIAL NO. U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. (MODIFIED) PATENT AND TRADEMARK OFFICE 078853-0302 10/029401 APPLICANT INFORMATION DISCLOSURE CITATION Roger A. Sabbadini FILING DATE **GROUP ART UNIT** (Use several sheets if necessary) 12/21/2001 1654 SEP 3 0 2007 **U.S. PATENT DOCUMENTS** XAMINER DOCUMENT FILING DATE SUB-MUNIALEN OREF DATE NAME **CLASS** NUMBER CLASS **APPROPRIATE** CC 6.210.976 04/03/2001 **A1** Sabbadini 436 518 5,929,039 07/27/1999 Woodcock, et al. CC A2 514 А3 5,677,288 10/14/1997 Marangos CC 514 , SEP 0 3 7007 CC 20010041688 11/15/2001 Waeber, et al. Α4 435 4,150,949 04/24/1979 Smith **A5** ሊፎ 23 LC 5,369,030 11/29/1994 Hannun, et al. Α6 435 240.2 CC Α7 5,631,394 05/20/1997 Wei, et al. 404 556 FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT SUB-REF DATE COUNTRY **CLASS** NUMBER **CLASS** YES NO CC A33 WO 98/57179 10/12/2000 PCT X WO 01/80903 11/01/2001 **PCT** A34 LC X A35 WO 99/12890 03/18/1999 PCT CC Ø メ CL WO 99/41266 08/19/1999 **PCT** A36 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Abe, et al., "Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of A69 glucosylceramide synthase," Kidney International, 57:446-454 (2000) Abe, et al., "Structural and stereochemical studies of potent inhibitors and glucosylceramide synthase and L.L A70 tumor cell growth," Journal of Lipid Research, 36:611-621 (1995) Abe, et al., "Use of Sulfobutyl Ether β-Cyclodextrin as a Vehicle for D-threo-1-Phenyl-2-decanoylamino-3-CC. morpholinopropanol-Related Glucosylceramide Synthase Inhibitors," Analytical Biochemistry, 287:344-347 A71 (2000)LL An, et al., "Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphotatidic A72 Acit," J. Biol. Chem., 273:7906-7910 (1998) An, et al., "Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids," FEBS C.C. A73 Letts., 417:279-282 (1997) DATE CONSIDERED 4/2004

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

EXAMINER

Page 2 of 21

5 DTO 4	140	II C DEDARTIE	WE OF COMME	- I -			OFFINA NO	Page 2 of 21
Form PTO-1 (MODIFIED)				SERIAL NO	10/029401 PL NO02			
(NIODIFIED)		PATENT AND IF	ADEMARK OFFIC		PPLICANT	0302	AF	FB_NOUZ
		ON DISCLOSURI	E CITATION			Roger A. Sa	bbadini	
OIF	E			F	ILING DATE		GROUP AR	TUNIT 1654
	(Use st	yeral sheets if nece	essary)		12/21/2	2001		ART_UNIT02
SEP 3	0 2002	ອ\ ພ C	U.S. PA	TENT	DOCUMENTS			
EXMINER INFOAL	REA C	DOCUMENT NUMBER	DATE		NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
25	A8	5,677,337	10/14/1997	Wei, et	al.	514	56	
İ	A9	6,323,201	11/27/2001	Carson	, et al.	514	234,2 RE	CENTE
	A10	4,937,232	06/26/1990	Bell, et	al.	514	26	CEIVE
	A11	4,816,450	03/28/1989	Bell, et	al.	514	25	EP 0 3 7007
	A12	5,331,014	07/19/1994	Kimura	, et al.	514		ENTER 1600/2
	A13	5,137,919	08/11/1992	lgarash	ni, et al.	514	642	<u> </u>
	A14	5,151,360	09/29/1992	Handa,	et al.	435	240.2	
	A15	6,187,562	02/13/2001	Duckwo	orth, et al.	+35	69.1	
	A16	5,851,782	12/22/1998	Hannur	n, et al.	514	360	
- -	A17	5,079,263	01/07/1992	Zeeck,	et al.	514	616	
	A18	5,444,087	08/22/1995	Patel, e	et al.	514	475	
	A19	6,284,798	09/04/2001	Amtma	nn, et al.	514	632	
	A20	6,306,911	10/23/2001	Wachte	er, et al.	546	193	
1	A21	6,051,598	04/18/2000	Shayma	an, et al.	514	428	
1	A22	5,919,687	07/06/1999	Chatter	iee	435	199	
1	A23	5,663,404	09/02/1997	Igarash		558	169	
	A24	5,260,288	11/09/1993	Igarash	i, et al.	514	114	
	A25	5,391,800	02/21/1995	lgarash	i, et al.	558	145	
	A26	5,430,160	04/04/1995	Boume	ndjel, et al.	549	510	
•	A27	5,248,824	09/28/1993	Igarash		564	292	
	A28	5,912,144	06/15/1999		ng, et al.	435	69,1	
	A29	6,130,067		Tsui	-	435	69.1	
 	A30	6,057,126	05/02/2000	Munroe	, et al.	435	69.1	
<u>C</u> r	A31	5,585,476	12/17/1996		nnan, et al.			
CC	A32	6,140,060	ļ	Chun, e		536 435	23.5	
						733	/ / /	
	1		i l				1	

Examiner: Louis Lee

	Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078853-0302		SERIAL NO. /0 /02940/ APPL_NO03				
			APPLICANT APPL NO03						
INFORMATION DISCLOSURE CITATION					Roger A. Sabbadini				
OIP	2				FILING DATE		GROUP AR	TUNIT	1654
		everal sheets if nece	ssary)		12/21/20	01		ART_UN	
SEP 3 0	2002		FOREIGN	I PAT	ENT DOCUMENTS				
SEP 3 0	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUB- CLASS	TRANS	LATIO! NO
CL PAGE	A37	WO 00/00593	01/06/2000	PCT				Х	
CL	A38	WO 00/21919	04/20/2000	PCT				X	
	A39	Intentionally	Left	Blar	k	REC	EIVE	D ^	
CC	A40	WO 00/52173	09/08/2000	PCT			0 3 2002	×	
CC	A41	WO 00/58448	10/05/2000	PCT]			×
CC	A42	WO 00/58491	10/05/2000	PCT		TECH CENT	'‡R 1600/29	100 	x
20	A43	WO 00/59517	10/12/2000	PCT				X	
<u> </u>	A44	WO 00/70028	11/23/2000	PCT				X	
<u></u>	A45	WO 00/72833 A2	12/07/2000	PCT					×
	A46	WO 01/04108	01/18/2001	РСТ				Х	
22	A47	WO 01/04139	01/18/2001	PCT				X	
<u> </u>	A48	WO 01/07418	02/01/2001	РСТ				X	
26	A49	WO 01/31029	05/03/2001	РСТ				X	
22	A50	WO 01/38295	05/31/2001	РСТ					×
CC	A51	WO 01/55410	08/02/2001	РСТ				×	
CC	A52	WO 01/57057	08/09/2001	РСТ				X	<u> </u>
C C	A53	WO 01/60990	08/23/2001	РСТ				X	
F.C.	A54	WO 01/72701	10/04/2001	PCT			1	X	
<u>C</u> C	A55	WO 01/85953	11/15/2001	PCT				X	
CC	A56	WO 97/44019	11/27/1997	PCT				X	
22	A57	WO 98/03529	01/29/1998	РСТ					X
ي ا	A58	WO 98/28445	07/02/1998	PCT				X	
22	A59	WO 98/40349	09/16/1998	PCT					X
CC	A60	WO 99/07855	08/11/1998	PCT					х
CC	A61	WO 99/12890	03/18/1999	PCT					Х
20	A62	WO 99/16888	04/08/1999	PCT				X	
	A63	WO 99/33972	07/08/1999	PCT	_ **-			X	
CC CC FXamin	A64	WO 99/38983	08/05/1999	PCT	, , , , , , , , , , , , , , , , , , , ,			X	
22	A65	WO 99/41265	08/19/1999	PCT					X


Page 3 of 21

023.215045

Form PTO-1- (MODIFIED)	MODIFIED) PATENT AND TRADEMARK OFFICE			078853-0302 APPL_NO03					
INF	ORMATI	ON DISCLOSURE	CITATION		APPLICANT Ro	oger A. Sal	obadini		
OIP					FILING DATE		GROUP AR	TUNIT	1654
		everal sheets if nece	ssary)		12/21/200)1		ART_UN	
SEP 3 0 S				PAT	ENT DOCUMENTS	<u> </u>			
SEP 3 0 1	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUB- CLASS	TRANS YES	LATION NO
CK-	A66	WO 99/41266	08/19/1999	PCT				Х	
CL	A67	WO 99/46277	09/16/1999	PCT					****
CC	A68	WO 99/61581	12/02/1999	PCT	RI	CEIA	ED	Х	
						SEP 0-3-20	12		
					TECH	CENTER 160	0/2900		
,									
· · · · · · · · · · · · · · · · · · ·									
								, .	
,									ļ
·									
								Fig. 11	
		a and made what w							
	<u> </u>	Lowar				TE: 4/0	<u> </u>	l	

023.215045

Form PTO-14	49	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO. 10/029401				
(MODIFIED)		PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04				
			APPLICANT					
INFO	RMAT	ION DISCLOSURE CITATION	Roger A. Sabbadini					
OIPE			FILING DATE	GROUP ART UNIT 1654				
	R se s	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04				
SEP 3 0 2007	ک ^و ر ب	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pa	ges, Etc.)				
SEP 3 U ZOU	x A74	An, et al., "Sphingosine 1-phosphate-induby G protein-coupled receptors Edg3 and						
CC	A75	Ancellin, et al., "Extracelluar export of spt the induction of angiogenic vascular matu M102841200).	ningosine kinase-1 enzyme: Sphin uration," <i>JBC Papers in Press</i> , Pul	ngosine 1 phosphate generation and blished 12/10/01 (manuscript				
£ .	A76	Andrieu-Abadie, et al., "L-carnitine prever inhibition of ceramide generation," FASEI		of cardiac myocytes: role of				
CC	A77	Arenz, et al., "Manumycin A and Its Analo ChemiBiochem., 2:141-143 (2001)	gues Are Irreversible Inhibitors of	Neutral Sphingomyelinase,"				
CC	A78	Arenz, et al., "Synthese des ersten selekt Chem., 112:1498-1500 (2000) (GERMAN		utralen Sphingomyelinase," <i>Angew</i>				
CC	A79		Arenz, et al., "Synthesis and Biochemical Investigation of Scyphostatin Analogues as Inhibitors of Neutral Sphingomyelinase," <i>Bioorganic & Medicinal Chemistry</i> , 9:2901-2904 (2001)					
<u> </u>	A80	Arenz, et al., "Synthesis of the First Selective Irreversible Inhibitor of Neutral Sphingomyelinase," Eur. J. Org. Chem., 137-140 (2001)						
<u>-</u> C	A81	Ariga, et al., "Role of Sphingolipid-mediat Research, 39:1-16 (1998)	ed cell death in neurodegenerativ	e diseases," Journal of Lipid				
CC	A82	Bajjalieh, et al., "Ceramide Kinase," Meth	ods in Enzymology, <u>311</u> :207-215	RECEIVE SEP 0 3 2002				
	A83	Intentionally Left Blank		TECH CENTER 1600/				
	A84	Intentionally Left Blank						
2	A85	Bawab, et al., "Molecular Cloning and Ch 275:21508-21513 (2000)	aracterization of a Human Mitocho	ondrial Ceramidase," J. Biol. Chem.,				
CC	A86	Bernardo, et al., "Purification and Charact Bovine Brain," <i>J. Biol. Chem.</i> , 275:7641-7	terization of a Magnesium-depend 647 (2000)	dent Neutral Sphingomyelinase from				
CC	A87	Betto, et al., "Sphingosylphosphocholine sarcoplasmic reticulum membranes," Biol		/calcium-release channel of cardiac				
CC	A88	Bielawska, et al., "(1S, 2R)-D-erhthro-2-(N Ceramidase," J. Biol. Chem., 271:12646-		panol as an Inhibitor of				
Examine	n: /	ouran (see	DATE: 4/200	4				



Form PTO-1	449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	Page 6 of 21 SERIAL NO. 10/029 40/		
(MODIFIED))	PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04		
			APPLICANT			
INF	ORMAT	ION DISCLOSURE CITATION	Roger A. Sabbadini			
OIP	<u>c</u> ~		FILING DATE	GROUP ART UNIT 1654		
/ 0	(Use s	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04		
SEP 3 0 2	002	OTHER DOCUMENTS (Including A	author, Title, Date, Pertinent Pag	ges, Etc.)		
SEP 3 0 2	A89	Bielawska, et al., "Ceramide Is Involved in Reperfusion," Am. J. Pathol., 151(5):1257	n Triggering of Cardiomyocyte Apo 7-1263 (1997)	ptosis Induced by Ischedia and		
CC	A90	Boudker, et al., "Detection and Character Plasma Membrane," J. Biol. Chem., 268:	ization of Ceramide-1-phosphate F 22150-22155 (1993)	Phosphatase Activity in Rat Lives		
CC	A91	Brady, et al., "The metabolism of sphin disease," Proc. Natl. Acad. Sci. USA, 55(ymatic deficiency in Niemann-Pick		
CC	A92	Brindley, et al., "Analysis of Ceramide 1-p Methods in Enzymology, 311:233-244 (19		sphate Phosphatase Activities,"		
CC	A93	Brownlee, C., "Intracellular signalling: sph (2001)	ningosine-1-phosphate branches or	ut," Current Biology, <u>11</u> :R535-R538		
LL	A94	Burton, et al., "Human antibodies from combinatorial libraries," Adv. Immunol., 57:191-280 (1994)				
CC	A95	Cain, et al., "Therapeutic Strategies to Reduce TNF-α Mediated Cardiac Contractile Depression Following Ischemia and Reperfusion," <i>J. Mol. Cell. Cardiol.</i> , 31:931-947 (1999)				
CC	A96	Caligan, et al., "A High-Performance Liqu and Related Compounds from Sphingosii Biochemistry, 281:36-44 (2000)	id Chromatographic Method to Meane Kinase Assays and Other Biolog	asure Sphingosine 1-Phosphate gical Samples," <i>Analytical</i>		
<u>-</u>	A97	Chan, et al., "Ceramide Path in Human Li	ung Cell Death," Am. J. Respir. Ce	II Mol. Biol., <u>22</u> :460-468 (2000)		
CL	A98	Chan, et al., "Purification and Charac Biochemistry, 39:4838-4845 (2000)	cterization of Neutral Sphingomy	velinase from Helicobacter pylori,		
CC	A99	Chatterjee, "Neutral Sphingomyelinase,"	Advances in Lipid Research, <u>26</u> :25	-49 (1993)		
CC	A100	Chatterjee, "Neutral Sphingomyelinase: p (1999)	past, present, and future," Chemistr	ry and Physics of Lipids, <u>102</u> :79-96		
CC .	A101	Chatterjee, et al., "Molecular Cloning, Characterization, and Expression of a Novel Human Neutral Sphingomyelinase," <i>J. Biol. Chem.</i> , <u>274</u> :37407-37412 (1999)				
CC	A102	Chau, et al., "Synthesis of Simple Aryl Ne (2001)	eutral Sphingomyelinase Inhibitors,	' Abstr. Pap. – Am. Chem. Soc.,		
	A103	Chun, "Lysophospholipid receptors: implic	cations for neural signaling," Crit. F	Rev. Neuro., 13(2):151-168 (1999)		
Exan	iner:	Town Lee	DATE!	+/2004		

Form PTO-1	1440	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	Page 7 of 21 SERIAL NO. 10 / 0 29 40 /		
(MODIFIED)		PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04		
(MODII ILD)	,	TATENT AND TRADEMARK OF THE	APPLICANT			
INF	ORMATI	ON DISCLOSURE CITATION	Roger A. Sabbadini			
PF	ACT.		FILING DATE	GROUP ART UNIT 1654		
/0	(ÚSÈ se	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04		
SEP 30	Appr Circ	OTHER DOCUMENTS (Including A	author, Title, Date, Pertinent Pages	i jii		
EXECUTE THE	, J	Chun, et al., "A Growing Family of Recep Lysophospholipids (LPs)," Cell Biochem.		(LPA) and other CH SEP		
	A105	Cordis, et al., "HPTLC analysis of sphing J. Pharm. And Biomed. Analysis, <u>16</u> :1189	jomylein, ceramide and sphingosine i 9-1193 (1998)			
20	A106	Cuvlilier, et al., "Suppression of ceramide Nature, 381:800-803 (1996)	e-mediated programmed cell death by			
<u>-</u>	A107	Dickson, et al., "Serine PalmitoyItransfera	ase," Methods in Enzymology, <u>311</u> :1-9	9 (1999)		
CC	A108	Edsall, et al., <i>Biochem.</i> , "N,N-Dimethylspl not of protein kinase C: modulation of cel 12898 (1998)				
CC	A109	Edson, et al., "The Aminoglycosides," <i>Mayo Clin. Proc.</i> , 74:519-528 (1999)				
<u> </u>	A110	Eichler, et al., "Peptide, peptidomimetic, a <u>15</u> :481-496 (1995)	and organic synthetic combinatorial lil	braries," Med. Res. Rev.,		
CC	A111	Fensome, et al., "A Neutral Magnesium Membranes and Reversibly Inhibited by F				
CC	A112	Fujii, et al., "Mg2+ binding and catalyti (Tokyo), 124:1178-1187 (1998)	ic function of sphingomyelinase from	m Bacillus cereus," J. Biochei		
20	A113	Fukushima, et al, "A single receptor enco cellular responses to lysophosphatidic ac				
<u> </u>	A114	Furneisen, et al., "Enzymological properti cerevisiae" Biochim. Biophys. Acta., 1484		atase from Saccharomyces		
CC	A115	Garcia-Ruiz, "Human placenta sphingo induces oxidative stress, glutathione depl	Garcia-Ruiz, "Human placenta sphingommyelinase, an exogenous acidic pH-optimum sphingomyelinase induces oxidative stress, glutathione depletion, and apoptosis in rat hepatocytes," <i>Hepatology</i> , 32:56-65 (2000)			
CL	A116	Gates, et al., "Serum amyloid p compor purified from the venom of the brown recl	nent: its role in platelet activation sti use spider (Loxosceles reclusa)," Tox	mulated by sphingomyelinase kicon, 28:1303-1315 (1990)		
CL	A117	Gatt, et al., "Niemann Pick disease: pres infantile form of the disease," J. Neuroche		sphingomyelinase in brain of th		
	A118	Gavrilenko, et al., "Nucleotide sequenc cereus BKM-B164," <i>Bioorg. Khim.</i> , 19:133	e of phospholipase C and sphingo 3-138 (1993)	myelinase genes from Bacillu		

023.215045

				Page 8 of 21	
Form PTO-14	49	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO. 10/029401	
(MODIFIED)		PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04	
11.15.0	INFORMATION DISCLOSURE CITATION		APPLICANT Roger A. Sabbadini		
OF FALL)RMAII \	ON DISCLOSURE CITATION			
· 0			FILING DATE	GROUP ART UNIT 1654	
0.0 2080	Wse se	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04	
SEP 3 0 200	EFIC	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pages	s, Etc.)	
CC PREDEMAR	A119	Geeraert, et al., "Conversion of dihydro 327:125-132 (1997)	ceramide into ceramide: involvement	t of a desaturase," Biochem. J.,	
CC	A120	Ghosh, et al., "Effects of gentamicin on s cells," <i>J. Biol. Chem.</i> , 262:12550-12556 (uman renal proximal tubular	
CC	A121	Ghosh, et al., "identification, partial purification partial purification skeletal muscle: Neutral sphingomyelination."			
CC	A122	Gilmore, et al., "A Bacillus cereus cytoly and sphingomyelinase genes: a nuclei (1989)			
CC	A123	Glickman, et al., "Molecular Cloning, Tiss Nerve Growth Factor-Related G-Protein-			
CC	A124	Goetzl, et al., "Eicosanoids and Other Bio Subfamily of G Protein-Coupled Cellular The Biochemistry and Biology of Lipid Ph	Receptors for Lysophospholipids and	Lysosphingolipids, Introduction:	
CC	A125	Gonda, et al., "The novel sphingosine 1- and -insensitive G-proteins to multiple sig			
CL	A126	Gonzalez-Zorn, et al., "The smcL gene o bacterial escape from the phagocytic vac			
LL	A127	Graler, et al., "EDG6, a Novel G-Protein- Lysophospholipids, Is Specifically Expres			
CC	A128	Gunther, "Myocardial contractility after in Pharma., 406:123-126 (2000)	nfarction and carnitine palmitoyltransfe	erase I inhibition in rats," Eur. J.	
CC	A129	Hakogi, et al., "Stereocontrolled synthe inhibitor," Org. Lett., 2:2627-2629 (2000)		nalogue as a sphingomyelinase	
CL	A130	Hanada, et al., "Specificity of Inhibitors Biosynthesis, in Intact Cells," <i>Biochemica</i>			
CC	A131	Hannun, et al., "Ceramide in the eukaryo	otic stress response," Cell Biology, 10	:73-80 (2000)	
CC	A132	Hannun, et al., "The Sphingomyelin Cycle 25:27-41 (1993)	e: A Prototypic Sphingolipid Signaling	Pathway," Adv. Lipid Res.,	
	A133	Intentionally Left Blank		SEP 0.3 (6)	
	L	<u> </u>		7 7 7 1	

Examiner Louve Les

DATE: 4/04 TECH CENTER : 600 2900

			•	Page 9 of 21	
Form PTO-		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078853 - 0302	SERIAL NO. 10 / 029 40) APPL NO04	
(MODIFIED	"	PATENT AND TRADEMARK OFFICE	APPLICANT	APPI_NO04	
INI	FORMATI	ION DISCLOSURE CITATION		. Sabbadini	
(P)			FILING DATE	GROUP ART UNIT 1654	
/o``_	10 3 s	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04	
SEP 3 0	2002 E	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pa	ges, Etc.)	
EL CC.	A3434	Hannun, et al., "Functions of Sphingolipic Science, 243:500-507 (1989)	ds and Sphingolipid Breakdown Pi	roducts in Cellular Regulation,"	
LL	A135	He, et al., "A Fluorescence-Based High-F Cermidase Activity," Analytical Biochemis		hy Assay to Determine Acid	
CC .	A136	Heringdorf, et al., "Stimulation of intracell sphingosine-1-phosphate receptors," Eur			
CC	A137	Hernandez, et al., "Rapid Activation of Ne Myocytes," Circ. Res., 86:198-204 (2000)		xia-Reoxygenation of Cardiac	
	A138	Intentionally Left Blank			
<u>``</u>	A139	Hetland, et al., "Phospholipase C from Bacillus cereus has sphingomyelinase activity," Scand J. Clin Lab Invest, 42(1):57-61 (1982)			
CC	A140	Higuchi, et al., "Acidic Sphingomyelinase Apoptosis and Nuclear Factor-кВ Activat			
CC	A141	Hinkovska-Glacheva, et al., "Activation of Concomitant Ceramide Accumulation Du Leukocytes," <i>Blood</i> , <u>91</u> :4761-4769 (1998	ring IgC-Dependent Phagocytosis		
CC	A142	Hise, et al., "Fatty Acyl Chain Compositio 77(3):768-773 (1986)	n in the Determination of Renal M	lembrane Oder," J. Clin. Invest.,	
É	A143	Hla, et al., "An Abundant Transcript Induced in Differentiating Human Endothelial Cells Encodes a Polypeptide with Structural Similarities to G-Protein-coupled Receptors," J. Biol. Chem., 265(16):9308-9313 (1990)			
<u> </u>	A144	Hofmann, et al., "Cloning and characterization of the mammalian brain-specific, Mg ^{2*} -dependent neutral sphingomyelinase," <i>PNAS</i> , <u>97</u> :5895-5900 (2000)			
CC	A145	Hofstadler, et al., "Multiplexed Screening of Neutral Mass-Tagged RNA Targets against Ligand Libraries with Electrospray Ionization FTICR MS: a Paradigm for High-Throughput Affinity Screening," <i>Anal Chem.</i> , 71:3436-3440 (1999)			
LL	A146	Holopainen, et al., "Sphingomyelinase A Biol. Chem., 275:16484-16489 (2000)	Activity Associated with Human F	Plasma Low Density Lipoprotein," J.	
22	A147	Horn, et al., "Sphingofungins E and F: No J. Antibiot. (Tokyo), 45(10):1692-1696 (19	ovel Serineoamitoyl Transferase Ir 992)	nhibitors from Paecilomyces variotti,"	

A148

DATE: 4/2004 SEP 113

Hoye, et al., "Synthesis (and Alternative Proof of Configuration) of the Scyphostatin C(1") Fragment," Organic Letters, 2:1481-1483 (2000)

Form PTO	-1449	U.S. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	SERIAL NO. 10/029401	
(MODIFIED)	PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04	
INFORMATION DISCLOSURE CITATION		APPLICANT			
ĮŅ.	FORMAT	ION DISCLOSURE CITATION	Roger A. Sabbadini		
OIPE ON DISCESSION DISCESSION			FILING DATE	GROUP ART UNIT 1654	
/		everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04	
SEP 3 0	2002	OTHER DOCUMENTS (Including A	author, Title, Date, Pertinent Pa	ges, Etc.)	
WY THE	ENPA149	Hudson, "Recombinant antibody fragmen	nts," Curr. Op. Biotechnol., <u>9</u> (4):39	5-402 (1999)	
CC	A150	Humpf, et al., "Acylation of naturally occur Formation of N-palmitoyl-aminopentol pro category of ceramide synthase inhibitor,"	oduces a toxic metabolite of hydro	lyzed fumonisin, AP1, and a new	
<u>L</u>	A151	Hunnan, "Functions of Ceramide in Coord (1996)	dinating Cellular Responses to Str	ress," <i>Science</i> , <u>274</u> :1855-1859	
CC	A152	Igarashi, "Functional Roles of Sphingosin Membrane Sphingolipid Signaling Pathwa Molecule," J. Biochem., 122:1080-1087 (ays. 1. Sphingosine-1-Phosphate		
CL	A153	Igarashi, "Sphinosine-1-Phosphate as an Center, University of Washington, Seattle		F. Huchinson Cancer Research	
CC	A154	Ikezawa, et al., "Studies on Sphingomyelinase of Bacillus Cereus. I. Purification and Properties," Biochin Biophys Acta, 528(2):247-256 (1978)			
CC	A155	Im, et al., "Molecular Cloning and Characterization of a Lysophosphatidic Acid Receptor, Edg-7, Expressed in Prostate," <i>Molecular Pharmacology</i> , <u>57</u> :753-759 (2000)			
CC	A156	lm, et al., "Characterization of a novel sph 14286 (2000)	lm, et al., "Characterization of a novel sphingosine 1-phosphate receptor, Edg-8," J. Biol. Chem., 275:14281-14286 (2000)		
77	A157	Izuhara, et al, "Studies toward the Total S Cyclohexenone Segment," Organic Letter		try to the Highly Functionalized	
CC C	A158	Jimbo, et al., "Development of a New (2000)	Inhibitor of Glucosylceramide Sy	nthase," <i>J. Biochem.</i> , <u>127</u> :485-49	
CC	A159	Johansen, et al., "Bacillus cereus strain S Acids Research, 16:10370 (1998)	SE-1: nucleotide sequence of the	sphingomyelinase C gene," Nucle	
`C	A160	Jonghe, et al., "Structure-Activity Relation Kinase," Bioorganic & Medicinal Chemisti	usip of Short-Chain Sphingoid Bas ry Letters, <u>9</u> :3175-3180 (1999)	es as Inhibitors of Sphingosine	
C	A161	Kajstura, et al., "Apoptotic and Necrotic Myocyte Cell Deaths Are Independent Contributing Variables of Infarct Size in Rats," <i>Lab. Invest.</i> , 74:86-107 (1996)			
	A162	Kanfer, et al., "The Metabolism of Sphin enzyme from rat liver tissue," J. Biol. Che.	ngomyelin. I. Purification and pro m., <u>241</u> :1081 (1966)	perties of a sphingomyelin-cleavin	
-2	A163	Katircioglu, et al., "Myocardial preservatio retroperfusion and carnitine," J. Cardiovas		on with coronary Ein CEIVE	
Exar	nine	Louis Les	DATE: 4/:		

Form PTO	-1449	U.S. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	SERIAL NO. 10/029401
(MODIFIE	D)	PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04
			APPLICANT	
INFORMATION DISCLOSURE CITATION		ION DISCLOSURE CITATION	Roger A. Sabbadini	
DF			FILING DATE	GROUP ART UNIT 1654
O C)(se several sheets if necessary)		everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04
SEP 30.	מסד הַר	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages	s, Etc.)
EC.	EMA 164	Kay, et al., "Identification of enzyme inhib Chem. High Throughput Screen, 4:535-5-	itors from phage-displayed combinat 43 (2001)	orial peptide libraries," Comb.
CC	A165	Kester, "Sphingolipid Metabolites and the 9:447-460 (1997)	Cellular Phenotype," Trends in Glyco	oscience and Glycotechnology,
20	A166	Kihara, et al., "Direct Measurement of Chand Reperfusion of the Intact Mammalian	anges in Intercellular Calcium Transi Heart," <i>Circ. Res.</i> , <u>65</u> (4):1029-1044	ents During Hypoxia, Ischemia, (1989)
LC .	A167	Kimura, et al., "Two Novel Xenopus Home Receptor Xenopus Oocytes and Mammal Manuscript MO11588200	ologs of Mammalian LPEDG-2 Functi ian Cells," JBC Papers in Press Publ	on as Lysophosphatidic Acid ished on-line 02/05/2001 as
<u>-</u>	A168	Kita, et al., "Reverse hydrolysis reaction of Biochimica et Biophysica Acta, 1485:111-	of a recombinant alkaline ceramidade 120 (2000)	of Pseudomonas aeruginosa,"
2	A169	Kohama, et al., "Molecular cloning and functional characterization of murine sphingosine kinase," <i>J. Biol. Chem.</i> , 273:23722-23728 (1998)		
CC.	A170	Kolesnick, et al., "Characterization of a Ceramide Kinase Activity from Human Leukemia (HL-60) Cells: Separation From Diacylglycerol Kinase Activity," <i>J. Biol. Chem.</i> , 265:18803-18808 (1990)		
1	A171	Krown, et al., "Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death," <i>J. Clin. Invest.</i> , <u>98</u> :2854-2865 (1996)		
	A172	Kubota, et al., "Accumulation of ceramide Japan J. Exp. Med., 59:59-64 (1989)	in ischemic human brain of an acute	case of cerebral occlusion,"
-C	A173	Kubota, et al., "Sphingomyelin changes in (1996)	rat cerebral cortex during focal ische	emia," <i>Neuro</i> . <i>Res.</i> , <u>18</u> :337-341
<u>-</u> C	A174	Lanterman, et al., "Characterization of sphisolation of SK-deficient mutants," Biochem	ningosine kinase (SK) activity in Saco m. J., <u>332</u> :525-531 (1998)	haromyces cerevisiae and
LC	A175	Lee, et al., "Improved Inhibitors of Glucosylceramide Synthase," J. Biol. Chem., 274:14662-14669 (1999)		
26	A176	Lee, et al., "Sphingosine 1-Phosphate Induces Angiogenesis: its Angiogenic Action and Signaling Mechanism in Human Umbilical Endothelial Cells," <i>Biochem Biophys Res. Commun.</i> , 264:743-750 (1999)		
C	A177	Lee, et al., "Lysophosphatidic acid and sp Am. J. Physiol. Cell Physiol., 278:C612-C6	hingosine 1-phosphate stimulate end 618 (2000)	othelial cell wound healing,"
C	A178	Intentionally Left Blank		RECEIVE
E.	-		TATEL III-	SEP 0.3 7660
[] Xan 215045	mer	forman Les	DATE: 4/2	TECH CENTER 1600:

E- DTO 4	440	U.O. DEDAOTAGUE OF COMMERCE		Page 12 of 21		
(MODIFIED)	149	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO. 10/029401		
(MODIKIED)	45	PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04		
INE	N GORMATEON DISCLOSURE CITATION		APPLICANT Roger A. Sa	abbadini		
E SEB 20	Str 3 v		FILING DATE	GROUP ART UNIT 1654		
ERTE	(Ust s	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04		
TRA	DEMIN	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages,	, Etc.)		
CC 3 0 2007	2 179	Lee, et al.,"Cell-cycle-dependent changes dephosphorylation in G2/M," Biochem. J.	s in ceramide levels preceding retinobl , 334:457-461 (1998)	lastoma protein		
CC	ي 4 180 هم	Lee, et al., "Effect of Ischemia on Calcium Indo 1. Correlation with Monophasic Action	n-Dependent Fluorescence Transients on Potentials and Contraction," <i>Circ.</i> , 7	in Rabbit Hearts Containing 8(4):1047-1059 (1988)		
CC CC	A181	Levade, et al., "Sphingomyelinases and N	liemann-Pick disease," J. Clin. Chem.	Biochem., <u>24</u> :205-220 (1986)		
22	A182	Li, et al., "The Human Acid Ceramidase C and Expression," <i>Genomics</i> , <u>62</u> :223-231	Li, et al., "The Human Acid Ceramidase Genes (ASAH): Structure, Chromosomal Location, Mutation Analysis, and Expression," Genomics, 62:223-231 (1999)			
FC	A183	Liliom, et al., "Sphingosylphosphocholine is a naturally occuring lipid mediator in blood plasma: a possible roin regulating cardiac function via sphingolipid receptors," <i>Biochem. J.</i> , 355:189-197 (2001)				
CC	A184	Lin, et al., "Identification of neutal and acidic sphingomyelinases in Helicobacter pylori, 15786 (1998)				
	A185	Intentionally Left Blank		SEP 0.8 H		
CC	A186	Linn, et al., "Regulation of de novo sphing Biochemical Society, pp. 831-835 (2001)	polipid biosynthesis and the toxic cons			
CC	A187	Lister, et al., "Interaction of sphingomyelir positions of the sphingosine backbone," E	nase with sphingomyelin analogs modi Biochimicha et Biophysica Acta, <u>1256</u> :2	ified at the C-1 and C-3 25-30 (1995)		
CŢ.	A188	Little, et al., "Surface display of antibodies	s," Biotechn. Adv., <u>12</u> :539-555 (1994)			
LL	A189	Liu, et al., "Molecular Cloning and Functional Characterization of a Novel Mammalian Sphingosine Kinase Type 2 Isoform," <i>J. Biol. Chem.</i> , <u>275</u> :19513-19520 (2000)				
FL	A190	Liu, et al., "Purification and Characterization of a Membrane Bound Neutral pH Optimum Magnesium dependent and Phosphatidylserine-stimulated Sphingomyelinase from Rat Brain," <i>J. Biol. Chem.</i> , 273:34472-34479 (1998)				
	A191	Liu, et al., "Sphingomyelinase Assay Usin (2000)	g Radiolabeled Substrate," Methods in	n Enzymology, <u>311</u> :164-167		
CC	A192	Liu, et al., "Advances in the signal transduction of ceramide and related sphingolipids," Crit. Rev. Clin. Lab. Sci., 36:511-573 (1999)				
LC_	A193	Liu, et al., "Inhibition of the neutral magne 272:16281-16287 (1997)	sium-dependent sphingomyelinase by	glutathione," J. Biol. Chem.,		
EVan		6	DATE, 11			

EXamur 023.215045 our les

Form PTO-	1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	Page 13 of 21	
(MODIFIED		PATENT AND TRADEMARK OFFICE	078853-0302	SERIAL NO. 10/029401 APPL NO04	
•			APPLICANT		
IN	FORMAT	ION DISCLOSURE CITATION	Roger A.	Sabbadini	
10	~		FILING DATE	GROUP ART UNIT 1654	
015	€ See s	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04	
orn 3 o	2002	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Page		
SEP 3 D	AWE U				
A C.C.	A#94	Liu, et al., "Glutathione regulation of neut death," J. Biol. Chem., 273:11313-11320	ral sphingomyelinase in tumor necro (1998)	sis factor-alpha-induced cell	
CC	A195	Lochhead, et al, "Fluorinated anesthetic e Kidney Int., <u>54</u> :373-381 (1998)	exposure "activates" the renal cortica	al sphingomyelinase cascade,"	
CC	A196	Luberto, et al., :Sphingolipid Metabolism	in the Regulation of Bioactive Molecu	ules," <i>Lipids</i> , <u>34</u> :S5-S11 (1999)	
CC	A197	Luberto, et al., "Sphingomyelin syntha diacylglycerol during SV40 transforma phosphatidylcholine-specific phopholipas	ation. Does sphingomyelin synt	hase account for the putative	
CC	A198	Lynch, et al., "Life on the edg," Trends Pt	narmacol. Sci., <u>20</u> :473-475 (1999)		
CC	A199	Magnelli, et al., "BCL-2 Overexpression A Murine," Bioch. Biophys. Res. Comm., 20	abolishes Early Calcium Waving Pred 14:84-90 (1994)	ceding Apoptosis in NIH-3T3	
fc	A200	Mandala, et al., "Isolation and Characterization of Novel Inhibitors of Sphingolipid Synthesis: Australifungin Viridiofungins, Rustmicin, and Khafrefungin," <i>Methods in Enzymology</i> , 311:335-348 (1999)			
CC	A201	Mandala, et al., "Molecular cloning and he sphingosine-1-phosphate and induces ce	caracterization of a lipid phosphohyd Il death," PNAS, 97:7859-7864 (2000	rolase that degrades 0)	
FL	A202	Mandala, et al., "Sphingosine-1-Phosphal 156 (2001)	te Phosphatases," Prostaglandins &	Other Lipid Mediators, 64:143-	
ĹĹ	A203	Mandala, et al., "Inhibition of Serine Paln 379 (1994)	nityltransferase Activity by Lipoxamy	cin," <i>J. Antibiot. (Tokyo)</i> , <u>47</u> :376	
C.C.	A204	Mandala, et al., "Viridiofungins, Novel In (1997)	hibitors of Sphingolipid Synthesis,"	J. Antibiot. (Tokyo), <u>50</u> :339-34	
CL	A205	Mandala, et al., "The Discovery of Austral Sporormiella australis. Producing Organis 48:349-356 (1995)	ifungin, a novel Inhibitor of Sphingan im, Fermentation, Isolation, and Biolo	ine N-Acyltransferase from ogical Activity," J. Antibiot.,	
CC	A206	Mandala, et al., "Khafrefungin, a novel inhibitor of sphingolipid synthesis," <i>J. Biol. Chem.</i> , 272:32709-32714 (1997)			
22	A207	Mandala, et al., "Sphingoid base 1-phosphate phosphatase: a key regulator of sphingolipid metabolism and stress response," <i>Proc. Nat. Acad. Sci.</i> , <u>95</u> :150-155 (1998)			
<u>LC</u>	A208	Mao, et al., "Cloning and Characterization Hydrolyzes Phytoceramide," J. Biol. Chem	of a Novel Human Alkaline Ceramid n., <u>276</u> :26577-26588 (2001)	ase: A Management and Enzymed Tha	
				SEP 0 3 /1-	

<u> </u>	40			Page 14 of 21		
Form PTO-14	49	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO. 10 1029 401		
(MODIFIED)		PATENT AND TRADEMARK OFFICE	078853-0302 APPLICANT	APPL_NO04		
INFO	RMAT	ON DISCLOSURE CITATION	Roger A. Sabbadini			
SIPE			FILING DATE	GROUP ART UNIT 1654		
∕o∵ ,	cyuse s	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04		
SEP 3 0 2002	, u	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Page	s, Etc.)		
A A	1.9209	Mao, et al., "Cloning and Characterization for Dihydroceramide," J. Biol. Chem., 275	n of a Saccharomyces cerevisiae Alk 5:31369-31378 (2000)	alline Ceramidase with Specificity		
FC	A210	Mao, et al., "Cloning of an Alkaline Ceran (CoA-Independent) Ceramide Synthase A	nidase from Saccharomyces cerevisi Activity," <i>The Journal of Biological Ch</i>	ae: An Enzyme with Reverse nemsitry, <u>275</u> :6876-6884 (2000)		
CC	A211	Mao, et al., "Molecular cloning and chaprotein from endoplasmic reticulum," Pro	Mao, et al., "Molecular cloning and characterization of SCaMPER, a Sphingolipid Ca2+ release-mediating protein from endoplasmic reticulum," <i>Proc. Natl. Acad. Sci. USA</i> , 93:1993-1996 (1996)			
CC	A212	Marks, et al., "Methods for Studying Glucosylceramide Synthase," Methods in Enzymologyl, 311:50-59 (1999				
	A213	Intentionally Left Blank		RECEIVE		
CC	A214	Martin, et al., "Neutral Magnesium-Dependant Sphingomyelinase from Liver Plasma Martin (இது இது and Inhibition by Ubiquinol," <i>J. Bioenerg. Biomember</i> , 33(2):143-153 (2001)				
CC	A215	Meacci, et al., "Receptor-mediated activation of phospholipase D by sphingosine 1-phosphate in skeletal muscle C2C12 cells," FEBS Letters, 457:184-188 (1999)				
<u>.</u> T	A216	Meldrum, "Tumor necrosis factor in the he	eart," <i>Am. J. Physiol.</i> , <u>274</u> :R577-R59	5 (1998)		
C	A217	Melendez, et al., "Human sphingosine kin distribution," <i>Gene</i> , 251:19-26 (2000)	nase: molecular cloning, functional ch	naracterization and tissue		
<u>-</u> C	A218	Meroni, et al., "Effect of N-Acetylsphingos myristoylamino)-1 phenyl-1-propanol on tl 625 (1999)	sine (C2) and the Ceramidase Inhibit he Regulation of Sertoli Cell Function	or (1S,2R)-D-erythro-2-(N-n," Journal of Andrology, <u>20</u> :619-		
<u> </u>	A219	Merrill, et al., "Activities of serine palmitoyltransferase (3-ketopsphinganine synthase) in microsomes from different rat tissues," <i>J. Lipid Res.</i> , <u>26</u> (5):617-622 (1985)				
SC	A220	Michel, et al., "Characterization of Ceramide Synthesis: A Dihydroceramide Desaturase Introduces the 4,5- TRANS-Double Bond of Sphingosine at the Level of Dihydroceramide," 272:22432-22437 (1997)				
CC	A221	Mingeot-Leclercq, et al., "Aminoglycoside: 43:727-737 (1999)	s: activity and resistance," <i>Antimicro</i>	bial Agents and Chemotherapy,		
<u>-</u>	A222	Mingeot-Leclercq, et al., "Aminoglycoside: 1012 (1999)	s: nephrotoxicity," <i>Antimicrobial Ager</i>	nts and Chemotherapy, <u>43</u> :1003-		
CC	A223	Mitsutake, et al., "Purification, Characterization, Molecular Cloning, and Subcellular Distribution of Neutral Ceramidase of Rat Kidney," <i>J. Biol. Chem.</i> , <u>276</u> :26249-26259 (2001)				

Examiner Lower Level 23.215045

Form PTO-		U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO. 10/6 29 40	
(MODIFIED)	PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04	
			APPLICANT		
TPIN	EORMAT	ION DISCLOSURE CITATION	Roger A. Sabbadini		
\o'\.	40		FILING DATE	GROUP ART UNIT 1654	
'	νω (USe s	several sheets if necessary)	12/21/2001	USPTO_ART_UNIT04	
SEP 30	JA FEIL	OTHER DOCUMENTS (Including A	outhor, Title, Date, Pertinent Pa	ges, Etc.)	
LC THAD	EMARITA A224	Mohan, et al., "Evidence that Neutral Sph Externally on the Plasma Membrane," Bi	ingomyelinase of Cultured Murine ochem Biophys Acta, 777(2):339-	Neuroblastoma Cells is Oriented 342 (1984)	
CL	A225	Mohler, et al., "Soluble Tumor Necrosis F Endotoxemia and Function Simultaneous 151(3):1548-1561 (1993)	actor (TNF) Receptors Are Effecti ly as Both TNF Carries and TNF A	ve Therapeutic Agents in Lethal Antagonists," <i>J. Immunol.</i> , RFCEIVE	
22	A226	Nakajima, et al., " <i>Biophysical J.</i> , <u>78</u> :319	A (2000)	SEP 0 3 2007	
CC	A227	Napoli, et al., "Ischaemic preconditioning hypermaebility and microcirculatory dama	of rat myocardium: effects on pos age," J. Clin. Bas. Cardiol., <u>1</u> :37-4;	tischaemid coronary endothelium 2 (1998)	
CC	A228	Nikolova-Karakashian, et al., "Ceramidas	es," Methods in Enzymology, <u>311</u> :	194-201 (1999)	
CE	A229	Ohta, et al.," Induction of apoptosis by sphingosine in human leukemic HL-60 cells: a possible endogenous modulator of apoptotic DNA fragmentation occurring during phorbol ester-induced differentiation," Cancer Res., 55:691-697 (1995)			
CC	A230	Ohta, et al., "A possible role of sphingosine in induction of apoptosis by tumor necrosis factor-α in human neutrophils," <i>FEBS Letters</i> , 355:267-270 (1994)			
22	A231	Okamoto, et al., "EDG1 Is a Functional Sphingosine-1-Phosphate Receptor That Is Linked via a G _{i/o} to Multiple Signaling Pathways, Including Phospolipase C Activation, Ca ^{2*} Mobilization, Ras-Mitogen-activated Protein Kinase Activation, and Adenylate Cyclase Inhibition," <i>J. Biol. Chem.</i> , <u>273</u> :27104-27110 (1998)			
CL	A232	Okamoto, et al., "EDG3 Is a Fur Sphingosylphosphorylcholine with Signa Biophys. Res. Commun., 260:203-208 (19	aling Characteristics Distinct fro	Sphingosine 1-Phosphate arm EDG1 and AGR16," <i>Biocher</i>	
ĊC_	A233	Okazaki, et al., "Characteristics and part sphingomyelinase activated in the early differentiation," <i>J. Biol. Chem.</i> , 269(6):407	signal transduction of 1α,25-dihyo	ic magnesium-independent, neutr droxyvitamin D3-induced HL-60 c	
	A234	Okino, et al., "Molecular Cloning, Sequent from Pseudomonas aeruginosa: Cloning of 274:36616-36622 (1999)	cing, and Expression of the Gene of A Ceramidase Homologue from	Encoding Alkaline Ceramidase mycobacterium Tuberculosis,"	
FL	A235	Olivera, et al., "Assaying Sphingosine Kinase Activity," Methods in Enzymology, 311:215-223 (1999)			
CC	A236	Olivera, et al., "Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens," <i>Nature</i> , 365:557-560 (1993)			
CC	A237	Oral, et al., "Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte," <i>J. Biol. Chem.</i> , 272:4836-4842 (1997)			
CC	A238	Oshefski, et al., "Glucosylceramide Synthase Inhibition Enhances Vincristine-Induced Cytotoxicity," Int. J. Cancer, 93:131-138 (2001)			
Exami	- 0 a	Louise Len	DATE:	4/2004	

	SEP 3 0 2		· · · · · · · · · · · · · · · · · · ·	Page 16 of 21	
		U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO. 10 029 40	
MODIFIEQ	TRADE!	APATENT AND TRADEMARK OFFICE	078853-0302 APPLICANT	APPL_NO04	
		ION DISCLOSURE CITATION		. Sabbadini	
			FILING DATE	GROUP ART UNIT 1654	
	(Use s	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04	
,		OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pa	nges, Etc.)	
cc.	A239	Parrill, et al., "Identification of Edg1 Rece Chem., 275:39379-39384 (2000)	ptor Residues That Recognize Sp	phingozine 1-Phosphate," J. Biol.	
CC C	A240	Pitson, et al., "Human sphingosine kinase and recombinant enzymes," Biochem J.,	e: purification, molecular cloning a 350:429-441 (2000)	and characterization of the native	
CC	A241	Pitson, et al., "Expression of a catalytical sphingosine kinase activation. A dominar (2000)	ly inactive sphingosine kinase mu nt-negative sphingosine kinase," J	tant blocks agonist-induced 7. Biol. Chem 275:33945-33950 RECEIVEI	
CC	A242	Raag, et al., "Single-chain Fvs.," FASEB	J., <u>9</u> :73-80 (1995)	SEP 0 3 7007	
SC	A243	Rani, et al., "Cell Cyle Arrest Induced by 2867 (1995)	an Inhibitor of Glucosylceramide S	TECH CEN LER 1000 2 Synthase," <i>J. Biol. Chem.</i> , <u>270</u> :2859-	
20	A244	Riley, et al., "Fermentation, Partial Purification, an Use of Serine Palmitoyltransferase Inhibitors from Isaria (=Cordyceps) sinclairii," Methods in Enzymology, 311:348-361 (1999)			
<u>`</u> C	A245	Romiti, et al., "Characterization of sphingomyelinase activity released by thrombin-stimulated platelets," Molecular and Cellular Biochemistry, 205:75-81 (2000)			
-C	A246	Runcie, et al., "A Short and Efficient Route (2001)	e to Novel Scyphostatin Analogue	s," Organic Letters, <u>3</u> :3237-3239	
L	A247	Sabbadini, et al.," Sphingosine is endoge Comm.: 193:752-758 (1993)	nous to cardiac and skeletal musc	cle," Biochem. Biophys. Res.	
ic.	A248	Saint-Joanis, et al., "Gene cloning shows sphingomyelinase and lecithinase activities	the alpha-toxin of Clostridium per es," Mol. Gen. Genet., 219(3):453-	fringens to contain both -60 (1989)	
i L	A249	Saito, et al., "Absolute Configuration of Scyphostatin," Organic Letters, 2:505-506 (2000)			
20	A250	Sakai, et al., "A devise for recording left ventricular contraction and electrocardiogram in nonworking isolated perfused rat heart," <i>Jpn J. Pharmacol.</i> , <u>28</u> :223-229 (1978)			
<u>`</u>	A251	Sato, "A new role of lipid receptors in vascular and cardiac morphogenesis," The Journal of Clinical Investigation, 6:939-940 (2000)			
£	A252	Sawai, et al., "Function of the Cloned Pu Phospholipase C," J. Biol. Chem., 274(53	utative Neutral Sphingomyelinase):38131-38139 (1999)	as Lyso-platelet Activating Factor-	
-C	A253	Sawai, et al., "Identification of ISC1 Saccharomyces cerevisiae," J. Biol. Chem.	(YER019w) as Inositol Phospho 7., <u>275</u> :39793-39798 (2000)	osphingolipid Phospholipase C in	

EXamine 023.215045

Louis Les

	SEP 3 0 20	18	•	Dece 17 of 24		
Form P	-1449	US. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	Page 17 of 21 SERIAL NO. 10 02 9 4 b		
(MODIFIE	3)	APATENT AND TRADEMARK OFFICE	078853-0302	APPL NO04		
•	C& THADEN	γ ε.	APPLICANT	 _		
IN	FORMATI	ON DISCLOSURE CITATION	Roger A	. Sabbadini		
			FILING DATE	GROUP ART UNIT /654		
	(Use s	everal sheets if necessary)	12/21/2001	USPTO_ART_UNITO4		
•		OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pa			
CC.	A254	Schissel, et al., "Zn2+-stimulated sphings sphingomyelinase gene," J. Biol. Chem.,	omyelinase is secreted by many c 271:18431-18436 (1996)	ell types and is a product of the ac		
CC	A255	Sergeyev, et al., "Lipid Spectrum of the N Aviakosm. Med, 15:71-74 (1981)	Sergeyev, et al., "Lipid Spectrum of the Myocardium of White Rats Exposed to Hypoxic Hypoxia," Kosm. I Aviakosm. Med, 15:71-74 (1981)			
CC	A256	Shayman, et al., "Glucosylceramide Sy (1999)	nthase: Assay and Properties,"	Methods in Enzymology, 311:42-4		
CC	A257	Shayman, et al., "Inhibitors of Glucosylce	Shayman, et al., "Inhibitors of Glucosylceramide Synthase," Methods in Enzymology, 311:373-387 (1999)			
CC	A258	Shinghal, et al., "Ceramide 1-Phosphate Phosphatase Activity in Brain," Journal of Neurochemistry, 61:2279-2285 (1993)				
CC	A259	Siehler, et al., "Sphingosine 1-Phosphate Activates Nuclear Factor-kB through Edg Receptors: Activation Through Edg-3 and Edg-5, but not Edg-1, in Human Embryonic Kidney 293 Cells," JBC Papers in Press Published 10/22/2001 in Manuscript MO1107220				
CC	A260	Siess, et al., "Lysophosphatidic Acid and Cardiovascular Diseases?" IUBMB Life, 4	Sphingosine 1-Phosphate: Two L 19:161-171 (2000)	ipid Villains Provoking		
CC	A261	Smith, et al., "Hypoxia, calcium fluxes, and inotropic state: Studies in cultured heart cells," <i>Amer. Heart J.</i> , 103(4):716-723 (1982)				
CC	A262	Smith, et al., "Purified Fumonisin B1 Dec Capillary Permeability in Swine," <i>Toxicolo</i>	reases Cardiovascular Function by ogical Sciences, <u>56</u> :240-249 (2000	ut does not Alter Pulmonary		
CC	A263	Spiegel, et al., "Sphingolipid metabolism and cell growth regulation," FASEB J., 10:1388-1397 (1996)				
8	A264	Intentionally Left Blank				
CC	A265	Spence, et al., "A new Zn2+-stimulated sphingomyelinase in fetal bovine serum," <i>J. Biol. Chem.</i> , 264(10):5358-5363 (1989)				
CC	A266	Spence, M.W., "Sphingomyelinases," Adv	v. Lipid Res., <u>26</u> :3-23 (1993)			
CC	A267	Spiegel, et al., "REVIEW: Roles of Sphing Biochemistry (Moscow), 63:69-83 (1998)	gosine-1-phosphate in Cell Growth	n, Differentiation, and Death,"		

Examiner C 023.215045

A268

DATE: 4/2004

Spiegel, et al., "Functions of a new family of sphingosine-1-phosphate receptors," *Bioch* 1484:107-116 (2000)

TECH CENTER TO DECI

SEP 3 0 2002 FORM TO-1449 4.S. DEPARTMENT OF COMMERCE (MODIFIED)

ATTY. DOCKET NO. 078853-0302

Page 18 of 21 SERIAL NO. 10/029 401 APPL_NO04

APPLICANT

Roger A. Sabbadini

FILING DATE

GROUP ART UNIT 1654

INFORMATION DISCLOSURE CITATION

\$.S. DEPARTMENT OF COMMERCE

(Use s	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04			
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages	, Etc.)			
A269	Sucheck, et al., "Combinatorial synthesis of aminglycoside libraries," Curr Opin Drug Discov Devel., 4:462-470 (2001)					
A270			ellum. Description of a new			
A271	Sugiyama, et al., "Sphingosine 1-phosphicanine heart," Cardiovasc. Res., 46:119-	ate induces sinus tachycardia and cor 125 (2000)	onary vasoconstriction in the			
A272	Sumnicht, et al., "Lipid Composition of Tra Muscle," Arch. Biochem. Biophys., 215:62	ansverse Tubular Membranes from No 28-637 (1982)	ormal and Dytophic Skeletal			
A273		Szulc, et al., "A facile regioselective synthesis of sphingosine 1-phosphate and ceramide 1-phosphate," Tetrahedron Letter, 41:7821-7824 (2000)				
A274	Tamura, et al., "Mass production of sphingomyelinase of Bacillus cereus by a protein-hyperproducign strain Bacillus brevis 47, and its purification," <i>J. Biochem. (Tokyo)</i> , 112(4):488-491 (1992)					
A275	Tanaka, et al., "Structural Elucidation of Scyphostatin, an Inhibitor of Membrane-Bound Neutral Sphingomyelinase," <i>J. Am. Chem. Soc.</i> , 199:7871-7872 (1997)					
A276	Tani, et al., "Purification and Characterization of a Neutral Ceramidase from Mouse Liver: A single Protein Catalyzes the Reversible Reaction in Which Ceramide is Both Hydrolyzed and Synthesized," J. Biol. Chem., 275:3462-3468 (2000)					
A277	Tazabekova, et al., <i>Bioorg. Khim</i> , <u>13</u> :648-653 (1987)					
A278	Tomita, et al., "Secondary structure of sphingomyelinase from Bacillus cereus," <i>J. Biochem. (Tokyo)</i> 108(5):811-815 (1990)					
A279	Tomiuk, et al., "Cloned mammalian neutral sphingomyelinase: Functions in sphingolipid signaling?" <i>Proc. Natl. Acad. Sci. (USA)</i> , 95:3638-3643					
A280	Torley, et al., "A turbidometric assay for phospholipase C and sphingomyelinase," <i>Anal Biochem.</i> , 222:461-464 (1994)					
A281	Tosaka, et al., "Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm," <i>Stroke</i> , 32:2913-2919 (2001)					
A282			nt Inhibitor of Dihydroceramide			
A283	Tsunoda, et al., "Early Fumonisin B1 Toxi Mice," J. Biochem. Mol. Toxicol., 12:281-2	city in Relation to Disrupted Sphingoli 289 (1998)	RECEIVEL BALB/c			
	A269 A270 A271 A272 A273 A274 A275 A276 A277 A278 A278 A280 A280 A281 A282	A269 Sucheck, et al., "Combinatorial synthesis (2001) A270 Sugita, et al., "Ceramidase and ceramide alkaline ceramidase," Biochim. Biophys. A271 Sugiyama, et al., "Sphingosine 1-phosphicanine heart," Cardiovasc. Res., 46:119-4272 Muscle," Arch. Biochem. Biophys., 215:6:119-4273 Szulc, et al., "A facile regioselective sate Tetrahedron Letter, 41:7821-7824 (2000) A274 Tamura, et al., "Mass production of sphingomyelinase," J. Am. Chem. Soc., 2016; and 3275 Sphingomyelinase," J. Am. Chem. Soc., 2016; and 275:3462-3468 (2000) A275 Tanaka, et al., "Purification and Characteriza Catalyzes the Reversible Reaction in White 275:3462-3468 (2000) A277 Tazabekova, et al., Bioorg. Khim, 13:648-468 (2000) A278 Tomita, et al., "Secondary structure of 108(5):811-815 (1990) A279 Tomita, et al., "Cloned mammalian neutral Acad. Sci. (USA), 95:3638-3643 A280 Torley, et al., "A turbidometric assay for pathogenesis of cerebral vasospasm." St. A281 Tosaka, et al., "Sphingosine 1-phosphate pathogenesis of cerebral vasospasm." St. A282 Triola, et al., "Synthesis of aCycloprop. Desaturase," Angew. Chem. Int. Ed., 40:1	A269 Sucheck, et al., "Combinatorial synthesis of aminglycoside libraries," <i>Curr Opin</i> (2001) A270 Sugita, et al., "Ceramidase and ceramide synthesis in human kidney and cereb alkaline ceramidase," <i>Biochim. Biophys. Acta.</i> , 398:125-131 (1975) A271 Sugiyama, et al., "Sphingosine 1-phosphate induces sinus tachycardia and concanine heart," <i>Cardiovasc. Res.</i> , 46:119-125 (2000) A272 Sumnicht, et al., "Lipid Composition of Transverse Tubular Membranes from No Muscle," <i>Arch. Biochem. Biophys.</i> , 215-628-637 (1982) A273 Szulc, et al., "A facile regioselective synthesis of sphingosine 1-phosphate <i>Tetrahedron Letter</i> , 41:7821-7824 (2000) A274 Bacillus brevis 47, and its purification," <i>J. Biochem. (Tokyo)</i> , 112(4):488-491 (1982) A275 Tanaka, et al., "Structural Elucidation of Scyphostatin, an Inhibitor of Membrane Sphingomyelinase," <i>J. Am. Chem. Soc.</i> , 199:7871-7872 (1997) A276 Tani, et al., "Purification and Characterization of a Neutral Ceramidase from Mc Catalyzes the Reversible Reaction in Which Ceramide is Both Hydrolyzed and 275:3462-3468 (2000) A277 Tazabekova, et al., <i>Bioorg. Khim</i> , 13:648-653 (1987) A278 Tomita, et al., "Secondary structure of sphingomyelinase from Bacillus of 108(5):811-815 (1990) A279 Tomiuk, et al., "Cloned mammalian neutral sphingomyelinase: Functions in sph. <i>Acad. Sci. (USA)</i> , 95:3638-3643 A280 Torley, et al., "A turbidometric assay for phospholipase C and sphingomyelinase (1994) A281 Tosaka, et al., "Sphingosine 1-phosphate contracts canine basilar arteries in vit pathogenesis of cerebral vasospasm," <i>Stroke</i> , 32:2913-2919 (2001) Triola, et al., "Synthesis of a Cyclopropene Analogue of Ceramide, a Poter Desaturase," <i>Angew. Chem. Int. Ed.</i> , 40:1960-1962 (2001)			

Examiner Lower Les

023.215045

DATE: 4/2004 SEP 037

SEP 3 0 2002

ATTY. DOCKET NO.

SERIAL NO. 10/02940/ APPL_NO04

Form (TO-1449 (MODIFIED)

S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

APPLICANT

Roger A. Sabbadini

FILING DATE

GROUP ART UNIT 1654

(Use several sheets if necessary)

INFORMATION DISCLOSURE CITATION

12/21/2001

078853-0302

USPTO ART UNITO4

	(058.5)	everal sneets if necessary)	12/21/2001	USPTO_ART_UNITO4				
•		OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages	, Etc.)				
LC.	A284	Uchida, et al., "Alutenusin, a Specific Neutral Sphingomyelinase Inhibitor, Produced by Penicillium sp. FO-7436," <i>J. Antibiotics</i> , <u>52</u> (6):572-574 (1999)						
CC	A285	Usta, et al., "Structural Requirements of C Ceramidase," <i>Biochemistry</i> , <u>40</u> :9657-9668	eramide and Sphingosine Based Inhi 3 (2000)	bitors of Mitochondrial				
CL	A286	Van Brocklyn, et al., "Sphingosine 1-phos the G protein-coupled receptor H218," J.		ite retraction are mediated by				
CL	A287	Van Veldhoven, "Sphingosine-1-phosphat	e Lyase" Methods in Enzymology, 31	<u>1</u> :244-254 (1999)				
FL	A288	Van Veldhoven, et al., "Human sphingosine-1-phosphate lyase: cDNA cloning, functional expression studies and mapping to chromosome 10q22 ¹ ," <i>Biochimica et Biophysica Acta</i> , 1487:128-134 (2000)						
CL	A289	Veldhoven, et al, "Sphingosine-Phosphate Lyase," Adv. Lipid Res., 26:69-98 (1993)						
SC	A290	Vivekananda, et al., "Sphingomyelin metabolites inhibit sphingomyelin synthase and CTP:phophocholine cytidylyltransferase," <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> , 2281:L91-L107 (2001)						
CC	A291	Walev, et al., "Selective killing of human monocytes and cytokine release provoked by sphingomyelinase (beta-toxin) of Staphylococcus aureus," <i>Infect. Immun.</i> , <u>64</u> :2974-2979 (1996)						
CC	A292	Wang, et al., "A Single Amino Acid Determines Lysophospholipid Specificity of the S1P1 (EDG1) and LPA1 (EDG2) Phospholipid Growth Factor Receptors," <i>JBC Papers in Press Published October 16, 2001</i> , Manuscript M107301200						
CL	A293	Wang & Merrill, et al., <i>Adv. Lipid Res.</i> , <u>26</u> :215-234 (1993)						
CL	A294	Winter, et al., "Making antibodies by phage display technology," <i>Annu. Rev. Immunol.</i> , <u>12</u> :433-455 (1994)						
CL	A295	Xia, et al., "High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL," <i>J. Biol. Chem.</i> , <u>274</u> :33143-33147 (1999)						
CC	A296	Xia, et al., "Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway," <i>PNAS</i> , <u>95</u> :14196-14201 (1988)						
LL	A297		Xu, et al, "Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha/cycloheximide-induced cerebral endothelial cell death," <i>J. Biol. Chem.</i> , <u>273</u> :16521-16526 (1998)					
FL	A298	Xu, et al., "Sphingosylphopsphorylcoline is Cell Biology, 2:261-267 (2000)	a ligand for ovarian cancer G-protein	RECEIVED Nature				

Examine Lowar Lea 023.215045

DATE: 4/04 SEP 03200

				530
SEP	3	0	2002	n 0,

Form PTO-1449 (MODINED)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 078853-0302

Page 20 of 21 SERIAL NO. /0/029 40 / APPL_NO04

APPLICANT Roger A. Sabbadini

FILING DATE

GROUP ART UNIT / 654

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)			12/21/2001	USPTO_ART_UNIT04
•		OTHER DOCUMENTS (Including	Author, Title, Date, Pertinent Pag	es, Etc.)
FL.	A299	Yada, et al., "Purification and biochemi guinea pig skin," <i>J. Biol. Chem.</i> , 270:12		und epidermal ceramidases from
CC	A300	Yamada, et al., "Nucleotide seque sphingomyelinase of Bacillus cereus,"		ia coli of the gene coding
CC	A301	Yamaji, et al., "Lysenin, a novel sphing	omyelin-specific binding protein," J. I	Biol. Chem., <u>273</u> :5300-5306 (199
LL	A302	Yamanaka, et al., "Acid Sphingomyelin 38:1753-1764 (1982)	ase of Human Brain; Purification to H	
	A303	Intentionally Left Blank		RECENTED SEP 0.3
AL	A304	Yamazaki, et al., Biochem. Biophys. Re	es. Commun., <u>268</u> :583-589 (2000)	TECH CENTER
CC	A305	Yatomi, et al., "Sphiongosine-1-Phosph Stimulated Human Platelets," <i>Blood</i> , <u>8</u> 6		d Released from Agonist-
<u>-</u> C	A306	Yatomi, et al., "Sphingosine 1-phospha constituent of human plasma and serui	te, a bioactive sphingolipid abundant n," <i>J. Biochem.</i> , <u>121</u> :969-973 (1997)	ly stored in platelets, is a normal
CC	A307	Yatomi, et al., "Sphingosine 1-phospha a platelet surface receptor with lysopho		
CC	A308	Yellon, et al., "Ischaemic preconditioni (1992)	ng limits infarct size in the rat heart,"	Cardiovasc Res., <u>26</u> :983-987
<u>C</u> L	A309	Yoshimura, et al., "Inhibition of Neutral in Hypoxic PC12 Cell Death," Journal of		
	A310	Intentionally Left Blank		
CC	A311	Zager, et al., "Decreased expression of proximal tubules," <i>Kidney Int.</i> , <u>52</u> :942-9	mitochondrial-derived H2O2 and hyd 52 (1997)	doxyl radical in cytoresistant
CC	A312	Zechner, et al., "MKK6 inhibits myocard Chem., 273:8232-8239 (1998)	dial cell apoptosis via a p38 MAP kina	se-dependent pathway," J. Biol.
CC	A313	Zelinski, et al., "Phosphatidylcholine b 11428 (1980)	iosynthesis in isolated hamster hear	1," J. Biol. Chem., <u>255(23)</u> :1142
EXan .215045	uner	Loine Les	DATE:	4/2004

6	45.00	A314	Zhang, et al., "Human Acid Ceramidase Gene: Novel Mutations in Farber Disease," <i>Molecular Genetics and Metabolism</i> , 70:301-309 (2000)
SE	H at	A315	Zhang, et al., "Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate," <i>Gene</i> , <u>227</u> :89-99 (1999)
'\(TRADENT	A316	Zhou, et al., "Indentification of the First Mammalian Sphingosine Phosphate Lynase Gene and its Functional Expression in Yeast," <i>Biochem. Biophys. Res. Comm.</i> , 242:502-507 (1998)
	CĹ	A317	Zweerink, et al., "Characterization of a Novel, Potent, and Specific Inhibitor of Serine Palmitoyltransferase," <i>J. Biol. Chem.</i> , <u>267</u> :25032-25038 (1992)

Examiner Lowar Lean

DATE: 4/2004

RECEIVED

SEP 0.3 700

TECH CENTER 1600-2900